Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested –NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company
Karyopharm asked the FDA to quickly approve using their medicine XPOVIO together with another drug to treat a serious blood disease. This shows the company believes the combination works well, but we won't know if the FDA agrees until they review it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.